All In Biotech

Drug Trial Radar · NCT02153229

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma

Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

52

Actual

Start

Jun 2, 2014

Primary completion

Dec 16, 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.

Conditions

  • Epitheliod Malignant Pleural Mesothelioma

Interventions

  • Photodynamic TherapyRadiation

  • Radical PleurectomyProcedure

  • ChemotherapyRadiation

  • Photofrin 2.0 mg/kgDrug

    If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival monthsTime frame: 4 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Roswell Park Cancer Institute

    Buffalo, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.